These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 38470964)

  • 41. Facial hyperpigmentation during imatinib therapy for gastrointestinal stromal tumor.
    Hamza I; Gaies E; Kastalli S; Daghfous R; El Aidli S
    Therapie; 2014; 69(3):245-7. PubMed ID: 24934821
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Well-differentiated systemic mastocytosis with KIT K509I mutation and uterus infiltration in an Asian woman with good response to imatinib.
    Zhao DD; Zhang L; Li WQ; Duan MH; Zhuang JL; Zhou DB
    Chin Med J (Engl); 2019 Aug; 132(16):2002-2003. PubMed ID: 31335472
    [No Abstract]   [Full Text] [Related]  

  • 43. Secondary mutations in the kinase domain of the KIT gene are predominant in imatinib-resistant gastrointestinal stromal tumor.
    Nishida T; Kanda T; Nishitani A; Takahashi T; Nakajima K; Ishikawa T; Hirota S
    Cancer Sci; 2008 Apr; 99(4):799-804. PubMed ID: 18294292
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Novel KIT mutation presenting as marked lentiginosis.
    Tran AK; Pearce A; López-Sánchez M; Pérez-Jurado LA; Barnett C
    Pediatr Dermatol; 2019 Nov; 36(6):922-925. PubMed ID: 31497890
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An immunohistochemical evaluation of c-kit (CD-117) expression in malignant melanoma, and results of imatinib mesylate (Gleevec) therapy in three patients.
    Alexis JB; Martinez AE; Lutzky J
    Melanoma Res; 2005 Aug; 15(4):283-5. PubMed ID: 16034306
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Imatinib-Sensitizing KIT Mutation in a Carney-Stratakis-Associated GI Stromal Tumor.
    Gasparotto D; Rossi S; Campagna D; Scavina P; Tiziano FD; Marzotto A; Toffolatti L; Vitelli CE; Amini M; Dei Tos AP; Maestro R
    J Clin Oncol; 2016 Apr; 34(11):e99-e103. PubMed ID: 25547508
    [No Abstract]   [Full Text] [Related]  

  • 47. Response to imatinib in KIT- and PDGFRA-wild type gastrointestinal stromal associated with neurofibromatosis type 1.
    Lee JL; Kim JY; Ryu MH; Kang HJ; Chang HM; Kim TW; Lee H; Park JH; Kim HC; Kim JS; Kang YK
    Dig Dis Sci; 2006 Jun; 51(6):1043-6. PubMed ID: 16865565
    [No Abstract]   [Full Text] [Related]  

  • 48. [Consensus on the medical treatment of gastrointestinal stromal tumors].
    Zhonghua Zhong Liu Za Zhi; 2007 Nov; 29(11):875-7. PubMed ID: 18396652
    [No Abstract]   [Full Text] [Related]  

  • 49. KIT as a therapeutic target in metastatic melanoma.
    Carvajal RD; Antonescu CR; Wolchok JD; Chapman PB; Roman RA; Teitcher J; Panageas KS; Busam KJ; Chmielowski B; Lutzky J; Pavlick AC; Fusco A; Cane L; Takebe N; Vemula S; Bouvier N; Bastian BC; Schwartz GK
    JAMA; 2011 Jun; 305(22):2327-34. PubMed ID: 21642685
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib.
    Akin C; Fumo G; Yavuz AS; Lipsky PE; Neckers L; Metcalfe DD
    Blood; 2004 Apr; 103(8):3222-5. PubMed ID: 15070706
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor).
    Heinrich MC; McArthur GA; Demetri GD; Joensuu H; Bono P; Herrmann R; Hirte H; Cresta S; Koslin DB; Corless CL; Dirnhofer S; van Oosterom AT; Nikolova Z; Dimitrijevic S; Fletcher JA
    J Clin Oncol; 2006 Mar; 24(7):1195-203. PubMed ID: 16505440
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Chronic mast cell leukaemia with exon 9
    Manthri S; Costello PN; Krishnan K
    BMJ Case Rep; 2020 Aug; 13(8):. PubMed ID: 32843387
    [No Abstract]   [Full Text] [Related]  

  • 53. Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants.
    Zhao J; Quan H; Xu Y; Kong X; Jin L; Lou L
    Cancer Sci; 2014 Jan; 105(1):117-25. PubMed ID: 24205792
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Inhibitors for ABL, KIT and PDGFR tyrosine kinases--imatinib, nitotinib, and dasatinib].
    Nishida T; Tsukazaki K
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():250-5. PubMed ID: 25831762
    [No Abstract]   [Full Text] [Related]  

  • 55. Secondary KIT mutations: the GIST of drug resistance and sensitivity.
    Napolitano A; Vincenzi B
    Br J Cancer; 2019 Mar; 120(6):577-578. PubMed ID: 30792534
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Successful treatment of progressive cutaneous mastocytosis with imatinib in a 2-year-old boy carrying a somatic KIT mutation.
    Hoffmann KM; Moser A; Lohse P; Winkler A; Binder B; Sovinz P; Lackner H; Schwinger W; Benesch M; Urban C
    Blood; 2008 Sep; 112(5):1655-7. PubMed ID: 18567837
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Secondary mutations of c-KIT contribute to acquired resistance to imatinib and decrease efficacy of sunitinib in Chinese patients with gastrointestinal stromal tumors.
    Gao J; Tian Y; Li J; Sun N; Yuan J; Shen L
    Med Oncol; 2013 Jun; 30(2):522. PubMed ID: 23456621
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Resistance to c-KIT kinase inhibitors conferred by V654A mutation.
    Roberts KG; Odell AF; Byrnes EM; Baleato RM; Griffith R; Lyons AB; Ashman LK
    Mol Cancer Ther; 2007 Mar; 6(3):1159-66. PubMed ID: 17363509
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group.
    Debiec-Rychter M; Dumez H; Judson I; Wasag B; Verweij J; Brown M; Dimitrijevic S; Sciot R; Stul M; Vranck H; Scurr M; Hagemeijer A; van Glabbeke M; van Oosterom AT;
    Eur J Cancer; 2004 Mar; 40(5):689-95. PubMed ID: 15010069
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Imatinib-induced nail hyperpigmentation in chronic myeloid leukemia.
    Prabhash K; Biswas G; Prasad N; Karant N; Sastry PS; Parikh PM
    Indian J Dermatol Venereol Leprol; 2006; 72(1):63-4. PubMed ID: 16481719
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.